MRCT to humanize antibody to treat SLE
SLE is a very important disease area, affecting over 1.5 Million people in the USA without any effective therapies. MRCT will use its proprietary humanization technology to generate the humanized clinical candidate from Ginkgo Biomedical Research Institute's mouse antibody.